drugset / Trial / NCT04409223

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

NCT04409223

Phase 3 Terminated 185 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.

Timeline

Start
2020-09-12
Primary completion
2022-03-25
Completion
2022-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Famitinib Small molecule Oral
Comparator Sunitinib Small molecule Oral